Cancellation of state registration. Insuman® Comb 25 GT

February 13, 2018

Active substances:

Insulin biphasic [human genetic engineering]

Trade names:

ICD-10:

IV.E10-E14.E10 Insulin-dependent diabetes mellitus

IV.E10-E14.E11 Non-insulin-dependent diabetes mellitus

Insuman Komb 25 GT, insulin, biphasic insulin, diabetes mellitus, treatment of diabetes mellitus, type 1 diabetes mellitus, type 2 diabetes mellitus, insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus

Ministry of Health of the Russian Federation in accordance with Article 32 of the Federal Law of 12.04.2010 No.61-FZ "On circulation of medicinal products" decided to abolish state registration and exclusion from the state register of medicinal products for medical use of the medicinal product (registration certificate P N011993 / 01 dated August 24, 2011 issued by Aventis Pharma Deutschland GmbH, Germany):

Insuman® Comb 25 GT (trade name of the medicinal product)

Double-phase insulin [human genetic engineering] (international non-proprietary or grouping or chemical name)

suspension for subcutaneous administration of 40 IU / ml, 100 IU / ml (dosage form, dosage)

Aventis Pharma Deutschland GmbH, Germany Brueningstrasse 50, D-65926, Frankfurt am Main, Germany (name and address of the location of the manufacturer of the medicinal product)

on the basis of a filing by an authorized legal entity of Sanofi-aventis Group, an application for the cancellation of the state registration of a medicinal product.